Patient factors associated with receiving reversal therapy in oral anticoagulant-related intracerebral hemorrhage.
Trine Apostolaki-HanssonTeresa UllbergBo NorrvingJesper PeterssonPublished in: Acta neurologica Scandinavica (2022)
Treatment with a reversal agent following OAC-ICH was related to several patient factors including type of OAC drug. We identified that only 48% of patients with NOAC-ICH received hemostatic treatment despite an increase in these cases. Further studies are required to guide the use of reversal therapies more precisely, particularly in NOAC-ICH.